Neuraxpharm Group
Script error: No such module "Draft topics". Script error: No such module "AfC topic".
 | |
| Private (GmbH/SL) | |
| ISIN | 🆔 |
| Founded 📆 | 1985 in Langenfeld, Rhineland, Germany |
| Founder 👔 | Dieter Gehrmann |
| Headquarters 🏙️ |
|
Number of locations | 19[1] (2022) |
Area served 🗺️ | Worldwide |
Key people | |
| Revenue🤑 | Approx. €480 million (2021) |
| Members | |
Number of employees | Approx. 900 (2022) |
| 🌐 Website | neuraxpharm |
| 📇 Address | |
| 📞 telephone | |
Neuraxpharm is a pharmaceutical company headquartered in Langenfeld, Germany and Barcelona, Spain. It was founded in 1985 and became a leading generics manufacturer in the 2000s. From 2016 to 2020, Neuraxpharm was owned by Apax Partners, which sold the company to Permira in 2020.
History[edit]
In 1985, Dieter Gehrmann founded the Neuraxpharm Arzneimittel GmbH & Co. KG. Neuraxpharm launched its first products with amitriptyline, haloperidol and promethazine for the psychiatric field.[2] After Gehrmann died in 2004, his heirs decided to sell the company to Andreas and Thomas Strüngmann.[3] They expanded the portfolio in the area of neurological products.[4]
In 2016, the Strüngmanns sold Neuraxpharm to funds of Apax Partners.[5] The new owners pushed ahead with the internationalization of the company, as well as mergers and acquisitions of several other European pharmaceutical companies.[6] In this context, the Neuraxpharm brand was introduced for all European subsidiaries and affiliated companies.[7] In 2020, global investment company Permira acquired Neuraxpharm.[8][9][10]
In 2020, Neuraxpharm acquired Buccolam.[11] In addition, Neuraxpharm became active in the medical cannabis market.[12] The company entered into a strategic partnership with the Israeli producer Panaxia.[13] Neuraxpharm was selected to supply medical cannabis for a pilot study conducted by the French National Agency for the Safety of Medicines and Health Products (ANSM).[14]
Company[edit]
Neuraxpharm operates as a limited liability company: Gesellschaft mit beschränkter Haftung (GmbH) in Germany; Sociedad Limitada (SL) in Spain. The company is managed by Jörg-Thomas Dierks (Chief Executive Officer) and Lluís Pérez (Chief Financial Officer), as well as other members of the executive committee.[15] In addition to the locations in Germany and Spain, there are commercial subsidiaries in other European countries, e.g. France, Italy and the United Kingdom. Production sites include the Laboratories Lesvi and Inke, both located in Spain.[16]
Products[edit]
Neuraxpharm specializes in pharmaceuticals and consumer healthcare products as well as medical cannabis and value-added medicines for the treatment and prevention of central nervous system (CNS) disorders.[17] The portfolio currently includes 150 different products in 2,000 different variants, such as antidepressants, antipsychotics, antiepileptics, tranquilizers, hypnotics, muscle relaxants, neuroleptics, and painkillers.[18] Dosage and dosage form can be adapted.[9]
References[edit]
- ↑ "Neuraxpharm Expands Its Business With Brain Therapeutics Buy", The Pharma Letter, 2022-03-08, retrieved 2022-04-12
- ↑ Bauer, Carolin (2013-06-10), "ZNS: Geld verdienen in der Nische", apotheke adhoc (in Deutsch), retrieved 2021-05-10
- ↑ "Familien und Dynastien: Diese Clans sind Pharma-Deutschland.", apotheke adhoc (in Deutsch), 2016-06-27, retrieved 2021-05-10
- ↑ Dribbusch, Barbara (2013-02-08), "Pillen, an die man glauben soll.", Die Tageszeitung (in Deutsch), p. 12
- ↑ Hollstein, Patrick (2016-09-07), "Neuraxpharm ist verkauft.", apotheke adhoc (in Deutsch), retrieved 2021-05-10
- ↑ "Deutscher Chef bei NuPharm. Namen des Tages: Jörg-Thomas Dierks", Handelsblatt (in Deutsch), p. 46, 2018-09-06
- ↑ "Nupharm heißt jetzt Neuraxpharm", CHEManager (in Deutsch), 2018-10-03, retrieved 2021-05-10
- ↑ Ruhkamp, Christoph (2020-09-23), "Permira schluckt Neuraxpharm", Börsen-Zeitung (in Deutsch), p. 9
- ↑ 9.0 9.1 Ruhkamp, Christoph (2021-04-27), "Finanzinvestor Permira steuert Neuraxpharm auf Börsenkurs.", Börsen-Zeitung (in Deutsch), p. 7
- ↑ "Permira Fonds übernehmen Neuraxpharm", Pharma Relations (in Deutsch), 2020-09-23, retrieved 2021-05-10
- ↑ "Neuraxpharm Buys Buccolam Brand From Takeda", The Pharma Letter, 2020-09-14, retrieved 2021-07-25
- ↑ Martinovic, Jelena (2021-12-08), "Panaxia & Neuraxpharm Launch Medical Cannabis Extracts In Europe, More Products To Come.", Benzinga, retrieved 2021-12-13
- ↑ "Cannabis-Versorgung: Neuraxpharm will bei Medizinalhanf mitmischen.", Ärzte Zeitung (in Deutsch), 2020-07-24, retrieved 2021-05-10
- ↑ Sinclair, Sarah (2021-01-29), "Neuraxpharm to Supply Medical Cannabis for French Pilot Study", Cannabis Health, retrieved 2021-07-25
- ↑ Executive Committee, Neuraxpharm, retrieved 2021-05-10
- ↑ Contact us, Neuraxpharm, retrieved 2021-05-10
- ↑ Psychiatric & Neurological Disorders, Neuraxpharm, retrieved 2021-05-10
- ↑ Portfolio, Neuraxpharm, retrieved 2022-04-12
External links[edit]
This article "Neuraxpharm" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Neuraxpharm. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
